lamivudine/zidovudine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 49 Diseases   8 Trials   8 Trials   104 News 


12»
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Trial completion, Enrollment change, Trial completion date:  Contribution of Dolutegravir to Obesity and Cardiovascular Disease (clinicaltrials.gov) -  Jul 27, 2023   
    P4,  N=10, Completed, 
    We saw a profound increase up to 1.2 Mio at Day 40. Recruiting --> Completed | N=30 --> 10 | Trial completion date: Jan 2022 --> Feb 2023
  • ||||||||||  lamivudine/zidovudine / Generic mfg.
    Trial completion, Trial completion date, Metastases:  A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) -  Jun 29, 2023   
    P2,  N=36, Completed, 
    Recruiting --> Completed | N=30 --> 10 | Trial completion date: Jan 2022 --> Feb 2023 Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Sep 2022
  • ||||||||||  acyclovir / Generic mfg., lamivudine/zidovudine / Generic mfg.
    Review, Journal:  Antiviral application of Carbohydrate Polymers: A review. (Pubmed Central) -  May 29, 2023   
    Additionally, the review describes the primary mechanism of drug delivery performance of carbohydrate polymers to improve the antiviral properties and pharmacokinetic behaviour of lamivudine, zidovudine, acyclovir, etc. The article discussed the role of carbohydrate polymers in mitigating virus-induced associated complications like bacterial infection, cardiovascular disorder, oxidative stress, and metabolic disorder. As a result, this work will provide valuable information to scientists, researchers, and clinicians for suitable carbohydrate polymer-based pharmaceutical development.
  • ||||||||||  ritonavir / Generic mfg., lamivudine/zidovudine / Generic mfg.
    Journal:  In Utero Antiretroviral Exposure and Risk of Neurodevelopmental Problems in HIV-Exposed Uninfected 5-Year-Old Children. (Pubmed Central) -  Mar 16, 2023   
    The specific regimen tenofovir/emtricitabine/ATV was associated with higher risk (cOR?=?2.31, CI: 1.08-4.97) relative to regimens using a zidovudine/lamivudine backbone combined with non-ATV ARVs. It remains important to monitor neurodevelopment of CHEU during early childhood and investigate the impact and the role of timing of in utero exposure to specific ARVs.
  • ||||||||||  lamivudine / Generic mfg., lamivudine/zidovudine / Generic mfg.
    Journal:  Lamivudine and Zidovudine-Loaded Nanostructures: Green Chemistry Preparation for Pediatric Oral Administration. (Pubmed Central) -  Feb 25, 2023   
    The drug incorporation was effective and the analyses using an electronic tongue indicated a difference in palatability between the nanotechnological samples in comparison with the drug solutions. In conclusion, PN was considered to have the strongest potential as a novel oral formulation for pediatric HIV treatment.
  • ||||||||||  efavirenz / Generic mfg., nevirapine / Generic mfg., lamivudine/zidovudine / Generic mfg.
    Retrospective data, Journal:  Rate of virological failure and HIV-1 drug resistance among HIV-infected adolescents in routine follow-up on health facilities in Cameroon. (Pubmed Central) -  Nov 2, 2022   
    The most common mutations were K103N (n = 21/42, 52.3%) resulting in high-level resistance to Efavirenz and Nevirapine, followed by M184V (n = 20/42, 47.6%) and thymidine analog mutations (n = 15/42, 35.7%) associated with high-level resistance to Lamivudine and Zidovudine respectively. The high rate of VF and HIVDR among ALHIV regularly followed in health facilities in Cameroon highlights the need to develop interventions adapted to an adolescent-centered approach to preserve future ART options.
  • ||||||||||  Dovato (dolutegravir/lamivudine) / ViiV Healthcare
    Variation in average unit prices (2020) of antiretroviral drugs in generic accessible low- and middle-income countries (Room 516/Channel 6) -  May 12, 2022 - Abstract #AIDS2022AIDS_396;    
    There are large variations in average procurement prices across regions and income groups of countries. In the current environment of flat lined international resources for HIV, countries must look for options to optimize their procurement cost and thereby reallocate the resources saved through supply chain optimization to other programme needs.
  • ||||||||||  lamivudine/zidovudine / Generic mfg.
    Journal:  Antiretroviral Prophylaxis: A Digestive Complication to Know. (Pubmed Central) -  Dec 21, 2021   
    An 8-year-old child experienced abdominal pain and melena due to duodenal and ileal ulcerations throughout antiretroviral prophylactic treatment after a needlestick injury. Mild to moderate adverse effects often occur with lamivudine and zidovudine, but more severe adverse effects such as intestinal ulcers resulting in melena after a prophylactic antiretroviral treatment may question the safety of the current guidelines.
  • ||||||||||  nevirapine / Generic mfg., lamivudine/zidovudine / Generic mfg.
    Journal:  Pregnancies Among the First Generation of Survivors of Perinatal HIV Infection. (Pubmed Central) -  Jul 2, 2021   
    Unplanned pregnancies, difficulties with adherence to ART, and drug resistance were identified challenges in the management of pregnancies among women with PHIV. This study highlights a gap in the reproductive counselling of adolescents with PHIV and the need for close follow-up and adherence support during pregnancy in this population.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    [VIRTUAL] Real-World DATA Analysis of Antiretroviral Treatment for HIV-Infected Adult Patients in Ukraine () -  Apr 12, 2021 - Abstract #ISPOR2021ISPOR_708;    
    CONCLUSIONS. ABC/VEN analysis of the real-world data showed that medicines for the antiretroviral treatment for adult HIV-infected patients in Ukraine correspond to the international treatment guidelines and regulatory lists which provides reliable additional evidence for the health technology assessment.
  • ||||||||||  Intelence (etravirine) / J&J
    [VIRTUAL] Real-World DATA Analysis of Antiretroviral Treatment for HIV-Infected Children in Ukraine () -  Apr 12, 2021 - Abstract #ISPOR2021ISPOR_707;    
    CONCLUSIONS. ABC/VEN analysis of the real-world data showed that medicines for the treatment for HIV-infected pediatric patients in Ukraine mainly correspond to the international treatment guidelines and regulatory lists which provides reliable additional evidence for the health technology assessment.
  • ||||||||||  ritonavir / Generic mfg., lamivudine/zidovudine / Generic mfg.
    Journal:  Zidovudine and lamivudine reach higher concentrations in ventricular than in lumbar human cerebrospinal fluid. (Pubmed Central) -  Mar 13, 2021   
    ABC/VEN analysis of the real-world data showed that medicines for the treatment for HIV-infected pediatric patients in Ukraine mainly correspond to the international treatment guidelines and regulatory lists which provides reliable additional evidence for the health technology assessment. Unexpectedly high concentrations of some antiretrovirals in the ventricular CSF, the site close to the brain parenchyma where HIV is located, should be considered when the cART regimen is aiming at CNS viral replication.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  Contribution of Dolutegravir to Obesity and Cardiovascular Disease (clinicaltrials.gov) -  Jan 13, 2021   
    P4,  N=30, Recruiting, 
    The paired t-test (n = 5) indicated no significant difference between the proposed and HPLC methods, hence comparable and can be used as an alternative method in routine quality determination of antiretroviral medicines. Not yet recruiting --> Recruiting | Trial completion date: Mar 2021 --> Jan 2022 | Initiation date: Jun 2020 --> Sep 2020 | Trial primary completion date: Jan 2021 --> Sep 2021
  • ||||||||||  lamivudine/zidovudine / Generic mfg.
    Enrollment closed, Trial primary completion date, Metastases:  A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) -  Oct 13, 2020   
    P2,  N=36, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2020 --> Mar 2020
  • ||||||||||  emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg., lamivudine/zidovudine / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date, Combination therapy:  Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV (clinicaltrials.gov) -  Dec 18, 2017   
    P2,  N=267, Completed, 
    N=24 --> 16 Recruiting --> Completed | N=100 --> 267 | Trial primary completion date: Dec 2010 --> Jun 2010 | Recruiting --> Completed | N=100 --> 267 | Trial primary completion date: Dec 2010 --> Jun 2010 | Recruiting --> Completed | N=100 --> 267 | Trial primary completion date: Dec 2010 --> Jun 2010
  • ||||||||||  lamivudine/zidovudine / Generic mfg.
    Enrollment open, Metastases:  A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) -  Nov 6, 2017   
    P2,  N=32, Recruiting, 
    Recruiting --> Completed | N=100 --> 267 | Trial primary completion date: Dec 2010 --> Jun 2010 | Recruiting --> Completed | N=100 --> 267 | Trial primary completion date: Dec 2010 --> Jun 2010 | Recruiting --> Completed | N=100 --> 267 | Trial primary completion date: Dec 2010 --> Jun 2010 Not yet recruiting --> Recruiting